5Clinical and Laboratory Standards Institute. Performance standards for antimicrobial Susceptibility testing[S]. M100-S16. CLSI, 2006.
6Patzer J, Toleman MA, Deshpande LM, et al. Pseudomonas aeruginosa strains harbouring an unusual metal blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998- 2001)[J]. J Antimicrob Chemother,2004,53(3) :451-456.
7[1]Takenouchi T,Sakagawa E,Sugawara M.Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones[J]. Antimicrob Agents Chemother, 1999, 43(2): 406-409.
8[2]Mouneimne H, Jarlier V, Cambau E, et al. Type Ⅱ topoisomerase mutations in ciprofloxacin-resistance strains of Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1999, 43(1): 62-66.
9[3]Li XZ, Livermore DM, Nikaiclo H. Role of efflux pumps in intrinsic resistance of Pseudomonas aeruginosa resistance to tetracycline, chloramphenicol and norfloxacin[J]. Antimicrob Agents Chemother, 1994, 38: 1732-1741.
10[4]Poole K, Bianco N, Neshat S, et al. Conservation of the multidrug resistance efflux gene oprM in Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1997, 41: 853-856.
